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MODULASI SITOKROM P450s OLEH ANTIKANSER SUB-FRAKSI 
STROBILANTHES CRISPUS DAN POTENSI INTERAKSI  





Sifat antikanser Strobilanthes crispus (S. crispus) mencadangkan potensi 
manfaat penggunaannya sebagai adjuvan dalam rawatan kanser payudara. Potenesi 
interaksi ubat herba (HDI) menimbulkan kebimbangan terhadap keselamatan dalam 
farmakoterapi kerana perubahan metabolisme sitokrom P450 (CYP) boleh 
mengakibatkan kegagalan rawatan dan ketoksikan. Dalam kajian ini, kesan modulasi 
in vitro sub-fraksi S. crispus (F3) terhadap lima CYP manusia (CYP2B6, CYP2C9, 
CYP2C19, CYP2D6 and CYP3A4) telah dikaji. Kajian menunjukkan tiada kesan 
perencatan yang ketara oleh F3 ke atas kesemua lima CYP tersebut dengan nilai IC50 
100 kali melebihi perencat CYP yang terdapat di pasaran. Penggunaan F3 dengan 
terapi kanser payudara konvensional yang menggunakan tamoxifen (TAM) boleh 
menjadi satu strategi untuk memaksimumkan keberkesanan terapeutik. Oleh itu, kajian 
interaksi antara F3 dan TAM adalah penting. Potensi HDI disiasat terlebih dahulu 
dengan menilai pengaruh F3 ke atas metabolisma TAM yang dimangkin oleh CYP 
secara in vitro. F3 menunjukkan perencatan jenis campuran yang lemah terhadap 4-
hidroksilasi TAM yang dimangkin oleh CYP2D6 dan N-desmetilasi TAM yang 
dimangkin oleh CYP3A4. Kesan gabungan TAM dan F3 ke atas viabiliti sel MCF-7 
kemudiannya dikaji. Kesan antagonistik timbal dikesan daripada rawatan gabungan. 
Hasil kajian ini mencadangkan kemungkinan interaksi antara F3 dan TAM dan juga 
metabolisma ubat-ubatan yang dimangkin oleh lima CYPs adalah rendah. Namun 
xv 
 
begitu, kajian lanjut diperlukan untuk menilai keberkesanan dan keselamatan rawatan 


























MODULATION OF CYTOCHROME P450s BY STROBILANTHES CRISPUS 
ANTICANCER SUB-FRACTION AND ITS POTENTIAL INTERACTION 





The anticancer property of Strobilanthes crispus (S. crispus) suggests its 
potential benefit as an adjuvant in breast cancer treatment. Potential herb-drug 
interaction (HDI) has always been a safety concern in pharmacotherapy as alteration 
in cytochrome P450 (CYP) mediated metabolism may lead to treatment failure and 
toxicity. In this study, the in vitro modulatory effect of a standardized sub-fraction of 
S. crispus (F3) on five human CYPs (CYP2B6, CYP2C9, CYP2C19, CYP2D6 and 
CYP3A4) was first investigated. Negligible inhibitory effects of F3 on all the five 
CYPs were observed, with IC50 values more than 100-fold higher in comparison to 
known CYP inhibitors. The use of F3 in conjunction with conventional breast cancer 
therapy using tamoxifen (TAM) could be a strategy to maximize the therapeutic 
efficacy. Thus, the investigation of the interaction between F3 and TAM is crucial. 
The potential HDI was first investigated through evaluating the influence of F3 on 
CYP mediated TAM metabolism in vitro. F3 demonstrated weak mixed-type 
inhibition towards CYP2D6 catalyzed TAM 4-hydroxylation and CYP3A4 catalyzed 
TAM N-desmethylation. The combined effect of TAM and F3 on the viability of MCF-
7 cell line was then investigated. A buffering antagonistic effect was observed from 
the combined treatment. The outcome of this study suggests the low possible 
interactions between F3 and TAM as well as the five CYPs catalyzed drug metabolism. 
Nevertheless, further studies are warranted to evaluate the efficiency and safety of the 





1.1 General introduction 
Herbs have been used since ancient times and they are still being taken for 
medicinal purposes. Some herbal medicines are used together with radiotherapy or 
chemotherapy to reduce the complications and side effects as well as to improve 
treatment effectiveness (Yin et al., 2013). A standardized sub-fraction of S. crispus 
(F3) has been reported to induce cytotoxicity and apoptosis on breast cancer cell lines, 
which includes MCF-7 and MDA-MB-231 (Yaacob et al., 2015). F3 also 
demonstrated visible inhibition towards mammary tumor growth in animal studies 
(Yaacob et al., 2015). With the anticancer properties found, S. crispus extracts have 
the potential to be used as an adjuvant in breast cancer therapy.  
Tamoxifen (TAM) is widely used for treating estrogen receptor (ER)-positive 
breast cancer. As with many anti-cancer agents, TAM use is related to various adverse 
effects such as elevated risk of endometrial cancer (Bergman et al., 2000; Hu et al., 
2015) and gastric adenocarcinoma (Chandanos et al., 2006). TAM is a prodrug and is 
metabolized by cytochrome P450 (CYP) into a few metabolites, which are N-
desmethyltamoxifen (NDT), (Z)-4-hydroxytamoxifen (HTF) and (Z)-endoxifen 
(EDF) (Jaremko et al., 2010), mainly through CYP2D6, CYP3A4 and CYP3A5. Co-
administration of TAM with paroxetine, an anti-depressant during treatment for breast 
cancer has been reported to result in higher risk of mortality, associated with 
irreversible inhibition of paroxetine on CYP2D6 (Kelly et al., 2010). To alleviate side 
effects or enhance the therapeutic effect of TAM, some patients also resort to 
alternative treatments such as the consumption of herbal products.   
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Hepatic elimination of drugs or their metabolites from the body occurs through 
metabolism by CYP enzymes or non-CYP enzymes. Aberrations in drug metabolism 
resulting from modulation of CYP enzyme activity is a contributing factor to drug-
drug interactions (DDI)  (Polasek et al., 2011; Tornio et al., 2019). Prediction of herb-
drug interaction (HDI) or DDI is critical in clinical drug development to minimize 
adverse drug reactions or loss of efficacy resulting from co-administration of 
supplementary and therapeutic drugs.  
1.2 Cytochrome P450 (CYP) 
CYP enzymes mediate the oxidative metabolism and biosynthesis of many 
endogenous and exogenous substances such as steroids, prostaglandins, drugs, 
environmental pollutants, alcohol, and organic solvents (McFadyen et al., 2004; 
Guengerich, 2017). CYPs are membrane-bound hemeproteins and individual CYP 
contains an iron-protoporphyrin Ⅸ molecule as the prosthetic group (Hasler et al., 
1999). The thiol-group of CYP serves as a ligand that changes the electron density of 
the heme porphyrin ring thereby activating atmospheric dioxygen (Hasler et al., 1999). 
The membrane-bound form of CYP reductase in eukaryotes mediates electron transfer 
from NADPH to the CYP heme center (Figure 1.1) (Das & Sligar, 2009). Oxidative 
metabolism is catalyzed by CYP through inserting an oxygen atom in an organic 
substrate and reducing another to water. 
The activity of a CYP enzyme may give a pleiotropic effect on the efficacy of 
a treatment by either activating prodrugs such as TAM to produce metabolites that 
have greater potency on treating a disease or inactivating the drugs so that their effects 
cannot be exerted (Desta et al., 2004; Vaclavikova et al., 2007). CYP19A1 enzyme 
which converts androgens to estrogens plays a role in estrogen-dependent diseases 












Figure 1.1: Schematic diagram of CYP catalyzed biotransformation of chemical 
compound. Two electrons from NADPH are transferred to the heme group of CYP via 
CYP reductase which has two flavin-containing domains, FAD and FMN or via 
cytochrome b5. CYP catalyzes the oxidative breakdown of substrate by inserting one 













cancer cells and CYP1B1 have been reported to inactivate tamoxifen (Vaclavikova et 
al., 2007). CYP enzymes are also critical in tumor development as some CYP enzymes 
enable the activation of tumor-inducing compounds, for example, 4-hydroxyestradiol 
or inactivation of anti-tumor agents (McFadyen et al., 2004). CYP1A1, CYP1B1 and 
CYP2E1 can promote tumor formation due to their capacity to activate pro-
carcinogens (McFadyen et al., 2004; Vaclavikova et al., 2007).  
CYPs from CYP1, CYP2 and CYP3 families play a major role in metabolizing 
over 90% of clinical drugs (Preissner et al., 2013). Human CYP2B6 represents the 
minor hepatic CYP accounting for around 2-5% of the total minor hepatic CYP, but it 
demonstrates approximately 300-fold expression variability (Zanger & Schwab, 2013). 
CYP2B6 catalyzed conversion of cyclophosphamide to 4-hydroxycycphosphamide, 
which is the precursor of cytotoxic metabolites (phosphoramide mustard and acrolein) 
(Zanger et al., 2007). CYP2C9 commonly metabolized drugs with a weakly acidic 
property such as the anticoagulant, anticonvulsants, oral antidiabetics and angiotensin 
receptor blockers (Zanger & Schwab, 2013). The prominent role of CYP2C19 in the 
metabolism of antidepressants such as imipramine and sertraline are known (Brøsen, 
2004). CYP2D6 contributes to metabolizing nearly 25% of currently available drugs 
(Zhou, 2009). This isoform displays a genetic polymorphism which consequently, 
leads to large discrepancies in drug metabolism catalyzed by CYP2D6 (Maréchal et 
al., 2008). With a large malleable active site and capability to catalyze different 
chemical reactions, CYP3A4 is able to convert various endogenous and exogenous 
compounds (Sevrioukova & Poulos, 2015). CYP3A4 is known as an efficient steroid 
hydroxylase in catabolizing endogenous steroids such as testosterone, progesterone 
and cortisol (Zanger & Schwab, 2013). In view of the critical role of P450s in phase Ⅰ 
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drug metabolism, alteration in CYP mediated reaction can lead to drug interactions 
(Lynch & Price, 2007).  
1.3 Enzyme inhibition 
CYP inhibition by chemicals can be characterized by performing enzyme 
inhibition kinetic studies. The experiment is conducted through using varied 
concentrations of substrate (S) and inhibitor (I), and the attained data is analyzed using 
the transformed Michaelis-Menten equation, including the Eadie-Hofstee plot (v vs. 
v[S]), the Lineweaver-Burk plot (1/v vs. 1/S) and the Dixon plot (1/v vs. S). Reversible 
enzyme inhibition is found as the common cause of DDI or HDI (Zhou et al., 2003). 
Reversible inhibitor which forms non-covalent interaction with enzyme surface 
demonstrates a transient inhibitory effect in which normal enzymatic functions will 
resume after the removal of inhibitors from the body (Saboury, 2009; Chen, Qin, et al., 
2014). Reversible enzyme inhibition can be categorized into competitive, non-
competitive, uncompetitive and mixed types.  
A competitive inhibitor has a similar structure to S, thus competing with S for 
the enzyme active site (Figure 1.2A). The inhibitory potency of this type of inhibitor 
can be attenuated through an increasing concentration of S ([S]). In non-competitive 
type inhibition, the binding of substrate to an enzyme is not influenced by the inhibitor 
as they bind to different sites of enzyme independently. The non-competitive inhibitor 
does not inactivate enzyme upon binding to it but exerts inhibitory effect through 
reducing the amount of enzyme available for drug metabolism (Houston et al., 2003; 
Ring et al., 2014). The scheme of non-competitive inhibition is presented in Figure 
1.2B. Since the inhibitor and substrate do not compete for the catalytic site, the 
inhibitory potency is not affected by alteration in [S].  
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Theoretical uncompetitive inhibition is uncommon in drug metabolism studies 
in vitro (Houston et al., 2003). The uncompetitive inhibitor only binds to the substrate-
bound enzyme (ES) (Figure 1.2C). Upon substrate binding to the enzyme, the structure 
of enzyme changes, therefore, exposes the inhibitor binding site (Saboury, 2009). 
Alteration in [S] can increase the degree of inhibition. Mixed-type inhibition affects 
substrate binding and reaction velocity (Ring et al., 2014). It is sometimes referred to 
as non-competitive inhibitor. Mixed-type inhibitors demonstrate different binding 
affinities towards free enzyme (E) and ES complex. Two dissociation constants are 
obtained from the two equilibria of reaction, which include: (A) Ki denotes the 
dissociation of the enzyme-inhibitor (EI) complex; (B) αKi denotes the dissociation of 
the inhibitor from the enzyme-substrate-inhibitor (ESI) complex (Figure 1.2D). When 
the constant value of α is equal to 1, the I demonstrates the same affinity for both the 
E and ES complex. When α value is greater than 1, the I has a greater affinity for the 
E, whereas the I binds more favorably to the ES complex when α value is less than 1 
(Copeland, 2005; Ring et al., 2014).  
1.4 Drug combination 
Drug combination is a strategy used for treating dreadful diseases including cancers, 
AIDS, hypertension and asthma with the purpose of attaining synergistic therapeutic 
effect (Chou, 2006; Foucquier & Guedj, 2015). For instance, the combination of 
rapamycin and chemotherapeutic agent (paclitaxel, carboplatin or vinorelbine) has 
synergistically enhanced the cytotoxicity in breast cancer cell lines due to aberrations 
in the phosphatidylinositol 3’-kinase/Akt pathway (Mondesire et al., 2004). Besides 
the combination of synthetic drugs, a combination of drug and natural product can also 
achieve therapeutic synergism. Aloe-emodin, derived from Aloe vera and Rheum 




Figure 1.2: Scheme and equation for reversible enzyme inhibition: (A) competitive 
inhibition; (B) non-competitive inhibition; (C) uncompetitive inhibition; (D) mixed-
type inhibition. 
E: free enzyme, S: substrate, P: product, I: inhibitor, ES: enzyme-substrate complex, 
EI: enzyme-inhibitor complex, ESI: enzyme-substrate-inhibitor complex, K: 






towards MCF-7 cell (Tseng et al., 2017). In addition to maximizing treatment efficacy, 
drug synergism minimizes toxicity through lowering doses of drugs and minimizing 
the occurrence of drug resistance (Roell et al., 2017). Confront difficulties in finding 
and approval of new chemical or molecular entities, the combined use of currently 
available drugs is a potential strategy to treat incurable diseases for instances, 
Alzheimer’s disease (Herrick & Million, 2007; Pangalos et al., 2007).  
The combination index (CI) method that can be used to quantitatively 
determined combined effects of drugs combination effects is developed based on the 
median effect principle of the mass-action law (Chou, 2010). The synergism of drug 
combination is depicted with CI value less than 1, additivity with CI value equal to 1 
and antagonism with CI value greater than 1 (Chou & Talalay, 1983; Chou, 2010). 
This method has been widely applied in studying drug combination effects over the 
last few decades (Roell et al., 2017).  
1.4.1 Herb-drug interaction (HDI) mediated by CYP 
Herbs are traditionally used in folk medicine and are continually used worldwide for 
promoting health and treating various diseases (Chen et al., 2012). Co-administration 
of herbal medicines with therapeutic drugs raises concerns about potential HDI, which 
could lead to significant clinical outcomes. Drug interaction mediated by modulation 
of CYP450 activities can result in adverse effects such as alteration in drug clearance 
thus leading to toxicity (Zlokarnik et al., 2005). St. John’s wort (SJW) is known to 
induce CYP3A4 and triggers clinically significant HDI (Borrelli & Izzo, 2009; Oga et 
al., 2016). Hyperforin in SJW exerts agonistic effect towards the pregnane X receptor 
(PXR) (Zhou et al., 2004). PXR together with the retinoid X receptor (RXR) forms a 
heterodimer when activated by hyperforin and then binds to the pregnane response 
element in the DNA as a transcription factor (Zhou et al., 2004; Kubin et al., 2005), 
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thus inducing CYP3A4 activity. Some observed HDI cases mediated by CYP are 
summarized in Table 1.1.  
1.4.2 In vitro CYP inhibition (IVCI) assay 
In vitro assessments of metabolism contribute to the understandings of 
biotransformation across different species. Utilization of in vitro systems provides the 
advantage of isolating metabolism pathways from other complex processes, such as 
phase Ι metabolism from phase ΙΙ metabolism which enables identification of 
enzyme(s) responsible for biotransformation of xenobiotics (Lipscomb & Poet, 2008). 
With the advantage, the use of in vitro system supports the clinical drug development 
in predicting DDI or HDI.  
For evaluation of inhibitory effects of drug candidates, in vitro systems using 
human liver microsomes (HLM) or recombinant CYPs are employed to monitor the 
effects on the metabolism of CYP substrates (Zhang et al., 2012). Screening for 
potential drug interaction has been performed using various IVCI assays, whereby the 
rate of drug metabolism by CYP enzymes have been analyzed using fluorescence 
(Ponnusankar et al., 2011), radiometric (Moody et al., 1999), liquid chromatography-
UV (LC-UV) (He et al., 2015) and liquid chromatography-tandem mass spectrometry 
(LC-MS) (Yadav et al., 2018) based methods. High selectivity and sensitivity of LC-
MS/MS for the monitoring target analytes has been widely utilized in IVCI (Pillai et 
al., 2013; Chen et al., 2017; Valicherla et al., 2019). Data obtained from in vitro CYP 
inhibition assessment can be used as a guideline for the clinical study of the interaction 
between drugs and can provide information for designing new drug candidates or 




Table 1.1: CYP mediated herb-drug interactions. 
Herbal medicine Extract or compound Modulatory effect on 
CYPs 
Clinical outcome References 
Hypericium perforatum 
(St. John’s wort) 
Standardized extract 
containing 0.3% hypericin 
 
Standardized extract 
containing 0.3% hypericin 
 
 
















Induction of CYP3A4  Elevated ratio of urinary 6β-
hydroxycortisol/cortisol 
 




Significant decrease in 
plasma concentration (Cp) of 
active SN-38 by 42% when 
SJW co-administered with 
irinotecan 
 
Reduction in mean of area 
under the concentration-
time curve (AUC) of 
indinavir by 57% 
 
Increase in imatinib CL by 
43% and decline in imatinib 
AUC by 30% 
 
Increase in CL of nevirapine 
by 35% 
 
(Roby et al., 2000) 
 
 



















(de Maat et al., 2001) 
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Table 1.1. Continued 
Herbal medicine Extract or compound Modulatory effect on 
CYPs 
Clinical outcome References 
Ginkgo biloba 
 (Ginkgo) 
Powder extract contained 
















Ginkgolic acids Ⅰ and Ⅱ 
Induction of mRNA 
expression of CYP2B1/2, 
CYP3A1 and CYP3A2 
 
Strong inhibition on 
CYP1A2, CYP2C9, 
CYP2E1 and CYP3A4 in 
vitro 
 






Induction of CYP3A4 
 
Inhibition on CYP1A2, 
CYP2C9, CYP2C19, 
CYP2D6 and CYP3A4 
activities in vitro 
 
Significant reduced the 
hypotensive effect of 







Decrease in AUC and 
maximum plasma 
concentration (Cmax) of 
midazolam by 34% and 
31%, respectively 















(Liu et al., 2011) 
 





Table 1.1. Continued 
Herbal medicine Extract or compound Modulatory effect on 
CYPs 
Clinical outcome References 
























Garlic caplets (GarliPure, 
maximum allicin formula) 
Induction of CYP1A2 and 
CYP2E1 expressions in 
mouse 
 
In vitro inhibition on 
CYP2C9*1, CYP2C19, 
CYP3A4, CYP3A5 and 




Induction of CYP2B1/2 
activity in rats and 
inhibition on CYP2E1 
activity in recombinant rat 
and human CYPs 
 
 
In vitro inhibition on 








Decrease in CL of 
docetaxel by 36% 
 
Significant elevation of 














Significant decrease in 
mean saquinavir AUC by 
51% and Cmax by 54% 




(Foster et al., 2001; 
Fasinu & Rapp, 2019; 





(Jin & Baillie, 1997; 






(Teyssier et al., 1999; Zou 
et al., 2002) 
 
 
(Piscitelli et al., 2002) 
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Table 1.1. Continued 
Herbal medicine Extract or compound Modulatory effect on 
CYPs 
Clinical outcome References 














500 mg ginseng 
Weak inhibition on 
CYP2C9, CYP2C19, 
CYP2D6 and CYP3A4 in 
vitro activities 
 
Increase in CYP2C9 and 

















Elevated Cmax of 
nifedipine by 29% 
 
Significant reduced the CL 
and Cmax of midazolam  
 









(Smith et al., 2001) 
 
 





1.5 Strobilanthes crispus 
Strobilanthes crispus (L) Bremek (Figure 1.3) from the family of Acanthaceae 
is a bush-like plant that can be found on riverbanks and abandoned fields and is native 
to countries such as Madagascar and Indonesia (Nurraihana & Norfarizan-Hanoon, 
2013). The common names of this plant include picah beling (Jakarta), kejibeling (Java) 
and pecah beling (Malaysia) (Abu Bakar et al., 2006). S. crispus has been used in folk 
medicine as an antidiabetic, anticancer, diuretic, antilytic, and laxative agent in 
Malaysia and Indonesia (Perry & Metzger, 1980; Nurraihana & Norfarizan-Hanoon, 
2013). The local people had boiled S. crispus leaves in water and drank the filtrates as 
traditional medicine. It has been reported that the indigenous peoples of Perak in 
Peninsular Malaysia eat the fresh leaves to strengthen the immune system (Samuel et 
al., 2010). 
A few products made from this herbal plant including herbal tea and capsules 
containing powdered crude leaves are now available in the health-food market. S. 
crispus has been increasingly consumed by the public due to its anti-carcinogenic, 
antioxidant properties and wound healing properties (Nurraihana & Norfarizan-
Hanoon, 2013). Anticancer activity of S. crispus including anti-proliferative and 
apoptotic activity in cancer cells has been previously reported (Abu Bakar et al., 2006; 
Yaacob et al., 2010). In the previous study conducted by Yaacob et al. (2015), F3 is 
the sub-fraction that showed the strongest cytotoxic effect on both MDA-MB-231 and 
MCF-7 cells among the five fractions obtained from dichloromethane (DCM) extract 
of S. crispus. F3 significantly inhibited mammary tumor growth (Yaacob et al., 2015) 
and activated the immune system (Yankuzo et al., 2018). Additionally, previous 
studies revealed that S. crispus extracts displayed no significant effects on hepatic and 






















constituents of F3 had been identified. These include lutein, 131-hydroxy-132-oxo-
pheophytin a, phytosterols (campesterol, stigmasterol and β-sitosterol), pheophytin a, 
and 132-hydroxy-pheophytin α.  
1.6 Breast cancer and use of tamoxifen (TAM) 
Advancement in diagnostic and therapeutic strategies has greatly reduced 
breast cancer mortality by 25% over the last two decades (Yue et al., 2013). However, 
the worldwide incidence of breast cancer remains the highest among all cancer types 
in women with approximately 2.1 million newly diagnosed cases and over 0.6 million 
deaths reported in 2018 (Bray et al., 2018). A comprehensive understanding of the 
mechanism underlying carcinogenesis is required to develop effective prevention 
strategies. The occurrence of breast cancer is primarily contributed by genetic factors, 
in which mutations in tumor suppressor genes including BRCA1, BRCA2, TP53, 
CHEK2 and PTEN are known (Thompson & Easton, 2004). In addition to genetic 
factors, hormones are also involved in the development of breast cancer (Clemons & 
Goss, 2001). Hormonal factors together with gene mutation were suggested promoting 
breast tumorigenesis through supporting cancer cell growth or involving in de-
differentiation of oncogenic epithelial cells (Wang & Di, 2014).  
1.6.1 Role of estradiol in breast cancer development 
Estradiol (E2) is a key steroid hormone in development of breast cancer (Yue 
et al., 2013). Progression of breast cancer was observed in different animal models 
administered with E2 (Hollingsworth et al., 1998; Zumoff, 1998). Abrogation of E2 
effect with anti-estrogenic agents and inhibition of its synthesis using aromatase 
inhibitors were found preventing contra-lateral breast cancer development (Howell et 
al., 2005; Thürlimann et al., 2005). Breast cancer associated with elevated estrogen 
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level is developed through either estrogen receptor (ER) dependent or independent 
mechanisms. 
1.6.2 Estrogen receptor (ER)-dependent breast cancer 
Estrogen can bind to one of the ER subtypes (ERα and ERβ) (Thomas & 
Gustafsson, 2011). ERα is the key ER subtype in mammary epithelium (Curtis Hewitt 
et al., 2000) which comprises a N-terminal domain (AF1), a DNA-binding domain, 
and a C-terminal ligand-binding region that has an AF2 domain (Kumar et al., 1987). 
Once estrogen binds to ERα, the activated ERα binds to the specific hormone-
responsive element in or near the gene promoter, thus triggers transcription of the gene 
(Saha Roy & Vadlamudi, 2012). ER-mediated mechanism enhances cell proliferation 
thus enables cancer development (Preston-Martin et al., 1990). Increase in cell division 
numbers raises possible errors in DNA replication and rapid cell division results in the 
ineffective repair of mutations (Preston-Martin et al., 1990). DNA adducts or breaks 
in fast-dividing cells could become fixed mutations and passed on to daughter cells 
(Preston-Martin et al., 1990).  
1.6.3 Estrogen receptor (ER)-independent breast cancer 
Carcinogenesis of estrogens via ER independent mechanism is facilitated by 
direct genotoxicity of estrogen metabolites (Russo et al., 2002; Russo et al., 2006). 
The direct genotoxic effect was evidenced by DNA points mutations resulting from 4-
OH estradiol in mutation assay using BB Rat2 embryonic cells (Zhao et al., 2006). 
Human CYP enzymes including CYP1B1, CYP1A1 and CYP3A4 at phase Ⅰ 
metabolism play critical roles in the oxidative metabolism of estrone (E1) and E2 to 
form 2,3- and 3,4-catechols (Yue et al., 2013). The catechols undergo secondary 
metabolism to produce 2,3- and 3,4-quinones which form DNA adducts (Cavalieri et 
al., 2006). Previous studies revealed that women at high risk or with breast cancer had 
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their urine detected with a high level of depurinating adducts (Gaikwad et al., 2008; 
Gaikwad et al., 2009). 
1.6.4 Tamoxifen (TAM) 
TAM is a selective estrogen receptor modulator (SERM) that binds 
competitively to ER and consequently inhibits the estrogen-regulated gene expressions 
(Criscitiello et al., 2010). TAM displays tissue-selective pharmacology, in which 
TAM acts as an estrogen antagonist in breast tissue and an agonist in the endometrium 
and bone tissues (Lewis-Wambi & Jordan, 2004). Furthermore, TAM inhibits 
angiogenesis, downregulates insulin-like growth factor 1 (IGF-1) and transforming 
growth factor (TGF) activities as well as induces programmed cell death (Ellis et al., 
1997; Karn et al., 2010). Imbalance of cell proliferation and cell loss due to slow cell 
proliferation may cause the regression of tumors (Criscitiello et al., 2010). TAM is 
used as hormone therapy for breast cancer at all stages and has successfully decreased 
contralateral breast cancer and reoccurrence risk by up to 50% (Martinkovich et al., 
2014; Bens et al., 2019). 
TAM is a prodrug that must be metabolized by CYP enzymes to produce two 
active metabolites: HTF and EDF (Gorman et al., 2013). Biotransformation of TAM 
mediated by CYP enzymes is depicted in Figure 1.4. EDF is equally as potent as HTF 
in inhibiting estrogen-responsive gene transcription (Desta et al., 2004; Gorman et al., 
2013). N- demethylation of TAM is found predominantly catalyzed by CYP3A4 and 
CYP2D6 with smaller contributions by CYP1A1 and CYP1A2 (Crewe et al., 2002; 
Desta et al., 2004). 4-hydroxylation of TAM is reported to be mainly catalyzed by 
CYP2D6, 2B6, and 2C9 (Wiseman & Lewis, 1996; Crewe et al., 2002; Desta et al., 
2004). The biotransformation of NDT to EDF is primarily mediated by CYP2D6 




Figure 1.4: CYP450 mediated biotransformation of tamoxifen to active metabolites 












Widespread use of TAM has raised the concern about the side effects, 
especially carcinogenicity of this drug (White et al., 1992; Phillips, 2001). High risk 
for developing endometrial cancer was found associated with long-term use of TAM 
in breast cancer patients (Chen, Kuo, et al., 2014). Two primary metabolites, alpha-
hydroxytamoxifen (α-HTF) and HTF were identified in TAM metabolic studies using 
rodent liver microsomes (Lim et al., 1994). The two metabolites can be further 
metabolized to form DNA adducts which potentially trigger carcinogenesis.  
1.7 Research objectives 
The potential for herb-drug interaction (HDI) resulting from co-administration 
of TAM with S. crispus is unknown. The aim of the current study is therefore to 
evaluate the modulatory effect of F3 on human CYP enzymes and the potential 
interaction between F3 and TAM using in vitro models. The findings can be used as a 
guide for further in vivo study on predicting the risk of using F3 in combination with 
therapeutic drugs. 
The specific objectives are: 
1. To investigate the modulatory effects of F3 on the enzymatic activity of 
CYP2B6, 2C9, 2D6, 2C19, and 3A4 via fluorescence-based screening 
2. To investigate the effect of F3 on the formation of substrate metabolites of 
major CYP enzymes using HPLC MS/MS 
3. To evaluate the effects of F3 on tamoxifen metabolism by HPLC MS/MS by 
measuring formation of 4-hydroxytamoxifen and N-desmethyltamoxifen 
4. To assess the cytotoxic effect of combination of F3 and tamoxifen on MCF-




MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals and reagents 
Vivid® CYP450 (2B6 blue, 2C9 blue, 2C19 blue, 2D6 blue and 3A4 blue) 
screening kits, CYP2C9, CYP2D6 and CYP3A4 BACULOSOMES® Plus Reagents 
were purchased from Life Technologies Corporation (Carlsbad, USA). Advanced 
RPMI 1640 medium, fetal bovine serum (FBS), penicillin-streptomycin (P/S) (10,000 
U/mL) and L-glutamine (200 mM), Dulbecco’s Phosphate Buffered Saline (DPBS) 
and trypsin-EDTA (0.25%) were purchased from Gibco Laboratories. TAM, (E/Z)-
EDF, propranolol, formic acid (FA) (liquid chromatography grade), quinidine and 
resazurin sodium salt were purchased from Sigma (Saint Louis, USA). Diclofenac 
(sodium salt), HDF, meclofenamate (sodium salt), NDT, (Z)-HTF, ketoconazole, 
miconazole (nitrate) and sulfaphenazole were purchased from Cayman Chemical (Ann 
Arbor, USA). Chloroform, dichloromethane, ethyl acetate, hexane (analytical grade), 
acetonitrile (liquid chromatography grade), methanol (liquid chromatography grade), 
silica gel 60 (0.040 – 0.063 mm), nicotinamide adenine dinucleotide phosphate 
(NADP) disodium salt, α-D-glucose-6-phosphate (G6P) (monosodium salt), glucose-
6-phosphate dehydrogenase (G6PD), potassium dihydrogen phosphate (KH2PO4), 
dipotassium hydrogen phosphate (K2HPO4) and magnesium chloride hexahydrate 
(MgCl2 * 6H2O) were purchased from Merck (Darmstadt, Germany).  
2.2 Plant material and F3 extract preparation 
The leaves of S. crispus were acquired from a cultivated source at Tasek 
Gelugor, Penang, Malaysia. The S. crispus extract (F3) was prepared as previously 
described  (Yaacob et al., 2015). In brief, the leaves of S. crispus were first cleaned, 
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air-dried and then pulverized into powder. The leaves powder was sequentially 
extracted with hexane followed by dichloromethane and was sonicated in Fisher 
Scientific ultrasonic bath FB15051 (Pittsburgh, USA) for 20 min followed an 
overnight soak. The extract obtained with dichloromethane was filtered and the solvent 
was evaporated in vacuo to yield dried dichloromethane extract. The extract was 
chromatographed on silica gel 60 through dry vacuum liquid chromatography. Step 
gradient elution was performed with hexane : chloroform : ethyl acetate : methanol 
(2:3:0:0 to 0:0:9:1, v/v/v/v, final volume of 300 mL each). The extract was dried using 
IKA RV 10 C rotary evaporator (Staufen, Germany) and kept in vials for storage at -
20°C. 
Qualitative analysis of F3 extract by HPLC-UV was performed to ascertain the 
presence of lutein, a chemical marker in the extract. An Agilent 1260 Infinity Diode 
Array Detector (California, USA) coupled to an Agilent 1260 Infinity ΙΙ HPLC system 
(California, USA) was used for sample analysis. A Thermo Scientific Hypersil 
GOLDTM C18 column (150 × 46 mm, 3 µm) (Waltham, USA) was used for separation 
with flow rate of 0.85 mL/min. Ultraviolet detection was set at 444 nm. The column 
thermostat was set at 40 °C. An aliquot (20 µL) of sample was injected for analysis. 
The mobile phase (MP) consisted of 0.1% formic acid in HPLC grade water (MP A) 
and acetonitrile (MP B). A stepwise gradient elution (Table 2.1) was employed for 
separation. 
2.3 CYP inhibition assays 
2.3.1 Vivid CYP inhibition assay 
The inhibitory effect of F3 on CYP2B6, CYP2C9, CYP2C19, CYP2D6 and 














Table 2.1: HPLC gradient elution program. 
Time  
(min) 
Mobile phase A  
(%) 
Mobile phase B  
(%) 






































blue and 3A4 blue) screening kits. The CYP BACULOSOMES reagent contains 
recombinant human CYP enzyme and NADPH-CYP reductase. A NADPH 
regeneration system (NRS) which contains 333 mM G6P and 30 U/mL G6PD converts 
NADP+ into NADPH. The substrate (BOMCC or EOMCC) was metabolized by CYP 
enzymes into highly fluorescent products (Figure 2.1).  
Procedures of the Vivid CYP450 enzyme assay were conducted according to 
the manufacturer’s instructions. Briefly, the stock solutions of F3 and known CYP 
inhibitors were serially diluted with reaction buffer provided in the kits to several 
concentrations (Table 2.2). A white NUNC® 96-well plate (Roskilde, Denmark) was 
used in this assay. In each well, a master pre-mix solution (50 µL) was added to F3 or 
solvent controls (40 µL). Pre-incubation of the reaction mixture at room temperature 
was set for 20 minutes. The reaction was started by addition of a mixture of substrate 
and NADP+ (10 µL). Known inhibitors of the five CYP enzymes as listed in Table 2.2 
were used as positive controls. The fluorescence readings were measured every 30 
seconds using an Agilent Cary Eclipse Fluorescence Spectrophotometer (California, 
USA) over different incubation time (listed in Table 2.2) with an excitation wavelength 
of 415 nm and an emission wavelength of 460 nm.  
 
The rate of reaction was calculated based on the fluorescence change per unit 
time over the linear range of reaction progress curve. Percentage of enzyme inhibition 
of test compounds was calculated using the formula as stated below: 
Percentage of enzyme inhibition = (1- 
X−B
A−B
 ) × 100% 
Where,  
 
